financetom
Business
financetom
/
Business
/
Canadian quantum computing firm Xanadu to list on Nasdaq via $3.6 billion SPAC deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canadian quantum computing firm Xanadu to list on Nasdaq via $3.6 billion SPAC deal
Nov 3, 2025 5:11 AM

Nov 3 (Reuters) - Xanadu Quantum Technologies will go

public on the Nasdaq through a merger with blank-check firm

Crane Harbor Acquisition Corp ( CHAC ) in a $3.6 billion deal,

the companies announced on Monday.

The Canadian quantum computing firm expects to fetch nearly

$500 million through the SPAC deal, including a $275 million

private investment in public equity.

Quantum computers are widely regarded to have the potential

to solve problems beyond the capability of classical computers.

The technology has progressed from theoretical promise and

fundamental challenges to practical commercial roadmaps this

year, with heightened focus from tech giants like IBM ( IBM ),

Microsoft ( MSFT ), and Google, which announced a

breakthrough algorithm last month.

Last month, U.S. banking giant JPMorgan Chase ( JPM )

also outlined quantum computing as part of a broader $1.5

trillion initiative.

Qubits - the building blocks of quantum computing - can

compute in minutes the reactions of trillions of atoms or cells

over time, making them invaluable for medicinal and materials

science breakthroughs. Classic supercomputers are estimated to

take thousands of years for similar tasks.

However, they are prone to errors that can quickly

overwhelm the useful computing work of a quantum chip, prompting

debates in the upper echelons of the tech industry on their

feasibility.

A slew of quantum computing companies have sought to go

public through SPAC mergers in recent years, sidestepping a

lengthy IPO process to list their shares.

In September, quantum computing startup Infleqtion agreed to

go public through a $1.8 billon SPAC deal with a blank-check

company led by veteran Wall Street dealmaker Michael Klein.

SPACs are shell companies that raise money through IPOs

to merge with a private company and take it public.

Morgan Stanley acted as financial advisor for Xanadu, while

JonesTrading was the capital markets advisor for Crane Harbor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Nov 4, 2025
Overview * Day One Q3 revenue of $39.8 mln beats analyst expectations * OJEMDA net product revenue rises 15% from Q2, driven by higher patient demand * Company raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln Outlook * Company raises OJEMDA full-year 2025 revenue guidance to $145-$150 mln Result Drivers * INCREASED DEMAND - OJEMDA net product revenue rose...
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Nov 4, 2025
Overview * Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln * Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year * Mirum updates 2025 revenue guidance to $500-$510 mln Outlook * Mirum updates 2025 revenue guidance to $500-$510 mln * Company expects VISTAS study topline data in Q2 2026 * Mirum anticipates...
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Nov 4, 2025
Overview * Mercury Systems ( MRCY ) fiscal Q1 rev grows 10.2% yr/yr, beating analyst expectations * Adjusted EPS for fiscal Q1 beats consensus, improving significantly year-over-year * Company announced $200 mln share repurchase program, reflecting confidence in future prospects Outlook * Mercury Systems ( MRCY ) did not provide specific future revenue or EPS guidance in the statement Result...
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Nov 4, 2025
Overview * Soleno Q3 net income at $26 mln, achieving profitability with VYKAT XR sales * VYKAT XR sales reach $66 mln in Q3, more than doubling from previous quarter * Company raised $230 mln through stock offering, strengthening financial position Outlook * Soleno expects selling, general and administrative expenses to rise post-VYKAT XR commercialization Result Drivers * VYKAT XR...
Copyright 2023-2026 - www.financetom.com All Rights Reserved